Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect

pharmafile | February 15, 2019 | News story | Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health 

Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials.

Brexpiprazole (Rexulti) did not meet its primary endpoint in two three-week, double-blind, placebo-controlled Phase 3 trials as a treatment for patients with manic episodes associated with bipolar I disorder.

The two trials involved around 650 bipolar I patients who had experienced an acute manic episode that required hospitalisation.

The studied did not perform better than placebos as measured by the Young Mania Rating Scale (YMRS). In both studies placebo performed substantially higher than anticipated.

Brexpiprazole was generally well tolerated during trials. The failure of trials in bipolar I disorder do not have any bearing on brexpiprazole’s use a treatment for major depressive disorder (MDD) or schizophrenia.

Louis Goss

Related Content


Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the …

Pharmanovia acquires CNS portfolio from Sanofi

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a …

NICE recommends nine digital treatment options for depression and anxiety

The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies …

Latest content